Rhode Island

Neurotech Pharmaceuticals, Inc. Granted Fast Track Designation from the U.S. FDA for the Treatment of Macular Telangiectasia type 2

CUMBERLAND, , Feb. 12, 2019 /PRNewswire/ -- Neurotech Pharmaceuticals, Inc. (Neurotech), a clinical-stage biopharmaceutical company focused on the development of transformative therapies for chronic eye diseases, announced today that the Food…
Continue Reading »